Kiniksa reports preliminary ARCALYST revenue of $122.5M for FY2022; cash $190.4M

Kiniksa Pharmaceuticals International, plc

ARCALYST net revenue Q4 2022 $39.9M, full-year $122.5M (unaudited).
Year-end 2022 cash, equivalents and ST investments $190.4M, funding into at least 2025.
Greater than 800 prescribers for recurrent pericarditis; 22% have prescribed for 2+ patients.
Payer approval rate >90%; approx 45% of patients who discontinued ARCALYST restarted therapy.
KPL-404 Phase 2 RA trial: 2 of 3 cohorts enrolled; proof-of-concept data expected 1H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kiniksa Pharmaceuticals International, plc reported the fourth quarter of 2022 results: revenue $39.9 million.

Period: the fourth quarter of 2022
Revenue: $39.9 million
Result: preliminary results

Exact text from the filing

ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kiniksa Pharmaceuticals International, plc reported the full year 2022 results: revenue $122.5 million.

Period: the full year 2022
Revenue: $122.5 million
Result: preliminary results

Exact text from the filing

ARCALYST net revenue was $39.9 million and $122.5 million for the fourth quarter and full year 2022, respectively (unaudited).

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-23-002072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.